SPY
769.86
+0.03%
QQQ
749.55
−0.00%
BTC/USD
84,890.12
+0.17%
DIA
511.70
+0.12%
GLD
380.52
+0.10%
TLT
77.53
+0.06%
US
Sign in
Register
My Account
Benzinga
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
EIGR
EIGR
Nasdaq Private Market
Private market price is not available
Privacy Manager
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
E
EIGR Analyst Price Targets - Benzinga
EIGR Analyst Price Targets
Wall Street analyst price targets and consensus rating for EIGR (EIGR).
Analyst Ratings News
PRO
Citigroup Maintains Buy on Eiger BioPharmaceuticals, Lowers Price Target to $3
Citigroup analyst Yigal Nochomovitz maintains Eiger BioPharmaceuticals (NASDAQ:EIGR) with a Buy and lowers the price target from $4 to $3.
Benzinga Newsdesk
Potential Upside For Eiger's Avexitide In Both PBH And CHI Indications: Analyst
Thursday, Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced it would focus its development efforts on advancing avexitide in
Vandana Singh
PRO
Baird Maintains Outperform on Eiger BioPharmaceuticals, Raises Price Target to $5
Baird analyst Brian Skorney maintains Eiger BioPharmaceuticals (NASDAQ:EIGR) with a Outperform and raises the price target from $3 to $5.
Benzinga Newsdesk
Starbucks To $94? Here Are 5 Other Price Target Changes For Wednesday
Citigroup raised the price target on Starbucks Corporation (NASDAQ: SBUX) from $90 to $94. Citigroup analyst Jon Tower maintained a Neutral rating on the stock. Starbucks shares fell 0.1% to $84.50 in pre-market trading.
Lisa Levin
PRO
BTIG Maintains Buy on Eiger BioPharmaceuticals, Lowers Price Target to $48
BTIG analyst Robert Hazlett maintains Eiger BioPharmaceuticals (NASDAQ:EIGR) with a Buy and lowers the price target from $57 to $48.
Benzinga Newsdesk
PRO
Eiger Biopharma Shares Up 50% Premarket; Low Float Play With ~30M Shares In Its Float; BTIG Earlier Raised Its Price Target From $45 To $57 On Stock
Benzinga Newsdesk